Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

and thank you for standing by. Welcome to the Kentra Bio first quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, we'll open up for questions. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, Dalia, Seamus, please go ahead. Thank you, Victor. Good afternoon, everyone, and thank you for joining us today to discuss Kintra Bio's first quarter of 2026 financial and business results. I'm Dalia Seamus from LifeSciAdvisors. Joining me on today's call are Thayne Wettig, Chief Executive Officer, David DeLucia, Chief Financial Officer, and Carol Gatham, Vice President of Product Development. Following the preferred remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about intrabio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. And our complete description of these and other material risks can be found in Kintra's bio...